AGC Biologics, a leading global contract development and manufacturing organization and global leader in clinical and commercial manufacturing of therapeutic proteins, opened the company's new global headquarters facility in Bothell, Washington.
The new global headquarters facility holds the company's corporate administrative offices and process development labs, with expansion space for additional mammalian and microbial manufacturing capacity. The site will also house a state-of-the-art R&D center dedicated to novel manufacturing technologies for faster development of therapeutic proteins.
"This was a wonderful occasion and a meaningful step for AGC Biologics in our continued expansion within the United States; as well as reaffirmation of our strong commitment to our operations within the dynamic Washington State life sciences community," said Gustavo Mahler, President & CEO of AGC Biologics. "We sincerely thank everyone to joined us to celebrate this momentous event, and we look forward to many exciting things to come as we continue our trajectory of growth and innovation."
According to company officials, “AGC Biologics offers deep industry expertise and unique customized services for the scale-up and cGMP manufacture of protein-based therapeutics; from pre-clinical to commercial production, for mammalian and microbial. Our integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage, and protein expression, including our proprietary CHEF1 Expression System for mammalian production.”
AGC Biologics noted it is the product of the convergence and integration of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company currently employs more than 850 employees worldwide. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Berkeley, California; Copenhagen, Denmark; Heidelberg, Germany; Yokohama, Japan; and Chiba, Japan.
SOURCE: AGC Biologics